1. Home
  2. WLY vs NVCR Comparison

WLY vs NVCR Comparison

Compare WLY & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Wiley & Sons Inc.

WLY

John Wiley & Sons Inc.

N/A

Current Price

$36.31

Market Cap

1.6B

ML Signal

N/A

Logo NovoCure Limited

NVCR

NovoCure Limited

N/A

Current Price

$12.02

Market Cap

1.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WLY
NVCR
Founded
1807
2000
Country
United States
Switzerland
Employees
5200
N/A
Industry
Books
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.5B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
WLY
NVCR
Price
$36.31
$12.02
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$28.08
AVG Volume (30 Days)
566.0K
2.6M
Earning Date
01-01-0001
05-20-2026
Dividend Yield
3.88%
N/A
EPS Growth
N/A
21.79
EPS
N/A
N/A
Revenue
N/A
$655,353,000.00
Revenue This Year
$0.02
$7.72
Revenue Next Year
$2.32
$6.74
P/E Ratio
$15.84
N/A
Revenue Growth
N/A
8.28
52 Week Low
$28.38
$9.82
52 Week High
$45.60
$20.49

Technical Indicators

Market Signals
Indicator
WLY
NVCR
Relative Strength Index (RSI) 71.70 45.69
Support Level $36.18 $10.86
Resistance Level $38.32 $14.13
Average True Range (ATR) 1.15 1.00
MACD 0.74 -0.06
Stochastic Oscillator 86.46 25.37

Price Performance

Historical Comparison
WLY
NVCR

About WLY John Wiley & Sons Inc.

John Wiley & Sons Inc is a publisher and a trusted leader in research and learning. The company segment includes: Research, which includes the reporting lines of Research Publishing and Research Solutions, and Learning includes the Academic and Professional reporting lines and consists of publishing, courseware, and assessments. Its industry-principal content, services, platforms, and knowledge networks are tailored to meet the evolving needs of its customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. The company empowers knowledge-seekers to transform today's obstacles into tomorrow's brightest opportunities. For more than two centuries, the company has been delivering on its timeless mission to unlock human potential.

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Share on Social Networks: